SP1 and cancer: Our previous observation that AP-1 and Sp1 are activated by TMPRSS4 led us to anticipate that TMPRSS4 may modulate cancer cell survival and that inhibition of TMPRSS4 may be an efficient therapeutic strategy for cancer treatment.